Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159143 · ClinicalTrials.gov registry record · Phase 2
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
A Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract, sponsored by Leonard Appleman.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03159143 is a Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract that has completed, run by Leonard Appleman. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03159143, a Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract, has completed, sponsored by Leonard Appleman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract. The primary endpoint was to assess response, as defined as a 25% reduction in measurable disease per the RECIST criteria. Measurable or evaluable objective response rate, time to disease progression and survival were also assessed.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Oxaliplatin
Study Locations (1)
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-12-17 |
| Est. Completion | 2009-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03159143
The ClinicalTrials.gov registry entry for NCT03159143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leonard Appleman, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Transitional Cell Cancer of the Urothelial Tract appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT03159143 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03159143 about?
NCT03159143 is a clinical study titled "Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract". The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract. The primary endpoint was to assess response, as defined as a 25% reduction in measurable di...
What is the current status of trial NCT03159143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2004-12-17. Estimated completion is 2009-12-02.
What conditions does trial NCT03159143 study?
This clinical trial studies the following conditions: Metastatic Transitional Cell Cancer of the Urothelial Tract.
What interventions are being tested in trial NCT03159143?
The interventions under investigation include: Docetaxel (DRUG), Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT03159143?
This trial is sponsored by Leonard Appleman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03159143 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.